Multisystem inflammatory syndrome in children related to COVID-19: An update regarding the presentation of two critically ill patients | Zendy

Pedro Taffarel | Zendy; Jorro Barón | Zendy; Ana Paula Rodríguez | Zendy; Jesica Widmer | Zendy; Claudia Meregalli | Zendy

Open Access

Multisystem inflammatory syndrome in children related to COVID-19: An update regarding the presentation of two critically ill patients

Author(s) -

Pedro Taffarel,

Jorro Barón,

Ana Paula Rodríguez,

Jesica Widmer,

Claudia Meregalli

Publication year - 2021

Publication title -

archivos argentinos de pediatria

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.236

H-Index - 19

eISSN - 1668-3501

pISSN - 0325-0075

DOI - 10.5546/aap.2021.eng.e26

Subject(s) - medicine , macrophage activation syndrome , systemic inflammatory response syndrome , systemic inflammation , presentation (obstetrics) , kawasaki disease , organ dysfunction , inflammation , covid-19 , hemophagocytic lymphohistiocytosis , immunology , vasoactive , toxic shock syndrome , multiple organ dysfunction syndrome , intensive care medicine , disease , shock (circulatory) , sepsis , infectious disease (medical specialty) , surgery , staphylococcus aureus , artery , biology , bacteria , genetics

Multisystem inflammatory syndrome in children related to COVID-19 is defined as the presence of persistent fever, inflammation, and organ dysfunction, with evidence of past or recent severe acute respiratory syndrome coronavirus 2 infection, and excluding other microbial causes. It overlaps with other inflammatory diseases (Kawasaki disease and toxic shock syndrome) and shares some features with hypercytokinemia conditions (hemophagocytic lymphohistiocytosis and macrophage activation syndrome). It differs from these and severe acute COVID-19 in its clinical presentation and laboratory parameters. It has a potentially severe course and may occur with cardiovascular failure; mortality is low (2 %). Here we provide an update on this syndrome and describe the presentation of two clinical cases with cardiovascular dysfunction who required vasoactive support and invasive ventilation. Serum lab tests showed inflammation parameters. Both patients were treated with intravenous immunoglobulin and systemic corticosteroids and had a favorable course.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research